When less is more - efficacy with less toxicity at the ED50

Title: When less is more - efficacy with less toxicity at the ED50
Creator: Dimmitt, Simon; Stampfer, Hans; Martin, Jennifer H.
Relation: British Journal of Clinical Pharmacology Vol. 83, Issue 7, p. 1365-1368
Publisher Link: http://dx.doi.org/10.1111/bcp.13281
Publisher: Wiley-Blackwell Publishing
Resource Type: journal article
Date: 2017
Description: The individualization of drug dosage tomaximize benefit and minimize risk is always a challenge since desired benefit is often associated with many dose-related adverse effects. Most disease is subacute and mild to moderate in severity. Doses that give around 50% of the maximum possible drug effect [the effective dose 50 (ED50)] often prove to be sufficient. An analysis of the dose–response relationship for most drugs shows that above the ED50, efficacy increases only marginally, whilst adverse effects continue to increase (Figure 1), especially with agonist agents. Using the lowest effective dosage is particularly desirable when drugs are used long term in prevention, as is the case with most cardiovascular drugs.
Subject: dose–response; effective dose 50; pharmaceutical marketing
Identifier: http://hdl.handle.net/1959.13/1354914
Identifier: uon:31384
Identifier: ISSN:0306-5251
Language: eng
Reviewed

		Thumbnail	File	Description	Size	Format